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Up to 50% of persons with HIV and a diagnosis of tu-
berculosis (TB) in Thailand die during TB treatment. In a 
prospective observational study, a team of physicians as-
cribed the cause of death after reviewing verbal autopsies 
(interviews of family members about events preceding 
death), laboratory data, and medical records. Of 849 HIV-
infected TB patients enrolled, 142 (17%) died. The cause 
of death was TB for 38 (27%), including 6 with multidrug-
resistant TB and 20 with disseminated TB; an HIV-associ-
ated condition other than TB for 50 (35%); and a condition 
unrelated to TB or HIV for 22 (15%). Twenty-three patients 
(16%) were judged not to have had TB at all. Death from 
all causes except those unrelated to TB or HIV was less 
common in persons receiving antiretroviral therapy (ART). 
In addition to increasing the use of ART, death rates may 
be reduced through expanded use of modern TB diagnostic 
techniques.
T
uberculosis (TB) is one of the most common causes of 
death among people living with HIV worldwide (1). In 
Southeast Asia, the death rate for HIV-infected TB patients 
during TB treatment is particularly high, ranging from 20% 
to 50% (2–5). HIV-infected patients in Southeast Asia are 
severely immunocompromised at the time of TB diagnosis, 
with a median CD4+ T-cell lymphocyte count (CD4) of 
54–57 cells/μL (2,6–9). With this degree of immunosup-
pression, it is likely, but not known, that opportunistic in-
fections other than TB contribute substantially to the high 
case-fatality rate.
Autopsy studies have helped delineate causes of death 
among people living with HIV, including HIV-infected 
TB patients, in sub-Saharan Africa (10–13). These stud-
ies found that the most common causes of death were 
TB, pneumonia, bacteremia, cerebral toxoplasmosis, and 
Pneumocystis jirovecii pneumonia (PCP). Autopsies are 
not routinely performed in HIV-infected persons in Asia, 
and data from Africa may not be generalizable to Asia. 
Malaria is much less common in Asia than in Africa, and 
HIV-infected TB patients have more severe immunosup-
pression and higher death rates than patients in Africa 
(2–4,6–9,14–19). Understanding actual causes of death 
may help with identifying effective interventions. In part, 
on the basis of autopsy studies of HIV-infected patients, 
programs began providing cotrimoxazole preventive ther-
apy (CPT) to HIV-infected TB patients in Africa. This 
therapy protects against malaria, PCP, toxoplasmosis, and 
bacterial pathogens. The reported reduction in death rates 
from this intervention is large in Africa, but less so in Asia.
(2,5,16,20–23). No published studies have demonstrated 
an association between CPT and reduced death rates in 
HIV-infected TB patients in Asia in the era of antiretrovi-
ral therapy (ART) (2,16; US Centers for Disease Control 
and Prevention [CDC], unpub. data).
Thailand has been greatly affected by the TB/HIV syn-
demic, i.e., 2 diseases acting synergistically to cause excess 
illness and death (24). Each year, TB develops in 91,000 
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persons, 15%–20% of whom are HIV-infected (25,26). To 
address the TB/HIV syndemic, Thailand recommends reg-
ular TB screening for persons with HIV, HIV testing for all 
TB patients, ART for all people with HIV who have a CD4 
cell count <250, and CPT for all TB/HIV patients. Access 
to HIV treatment has been expanded nationwide. Howev-
er, in practice, not all patients are treated according to the 
guidelines (2). To understand the causes of death in persons 
with HIV and a diagnosis of TB and identify possible inter-
ventions to reduce death rates, we conducted a prospective, 
multicenter, observational study of HIV-infected patients 
being treated for TB in Thailand. 
Methods
Study Setting and Population
We conducted a cohort study of HIV-infected TB 
patients at the national infectious diseases referral hos-
pital (Bamrasnaradura Institute) in Nonthaburi province 
and at public TB treatment facilities in Bangkok, Phuket, 
and Ubon-Ratchathani provinces. These facilities ranged 
from outpatient clinics to large public hospitals. There are 
no known, substantial differences in the HIV or TB epi-
demics across these 4 provinces. At all sites, treatment for 
HIV and TB were available from government providers 
using standardized government-recommended regimens. 
TB patients were eligible if they were HIV-infected, not 
pregnant, not incarcerated, >18 years of age, and receiv-
ing anti-TB treatment <4 weeks before study enrollment. 
Patients consenting to study enrollment were followed up 
from TB treatment initiation to the end of TB treatment. 
For this study, patients received the usual care for TB, HIV, 
and other diseases according to physician preference. We 
did not intervene to modify routine clinical practice. This 
study was approved by the ethical review committees of the 
Bangkok Metropolitan Administration, the Thailand Min-
istry of Public Health, and CDC.
Data Collection and Laboratory Studies
Patients had 3 study visits: at the beginning of TB 
treatment, at the end of the intensive phase of TB treatment 
(usually 2 months after start of treatment), and at the end of 
TB treatment (usually 6 months after treatment initiation). 
At the beginning of treatment, patients were interviewed 
using standardized study forms that asked about demo-
graphic characteristics, past and present medical history, 
knowledge and attitudes related to TB and HIV, and sexual 
behavior history and drug-use history. At every study visit, 
patients received a physical examination and provided in-
formation about medications taken and any adverse events 
experienced since their previous visit. Study staff reviewed 
medical records for any health-related problem that oc-
curred between study visits.
At enrollment, blood samples were tested for liver 
function enzymes, viral hepatitis, complete blood count, 
and CD4 count. Sputum and specimens from extrapulmo-
nary sites were collected for acid-fast bacilli smear and for 
mycobacterial culture, identiﬁ  cation, and drug-susceptibil-
ity testing.
Although the standard TB treatment regimen in Thai-
land is 2 months of rifampicin, isoniazid, pyrazinimide, and 
ethambutol followed by 4 months of rifampin and isoni-
azid, some providers chose to use nonstandard regimens. 
Therefore, we categorized regimens used into those likely 
to be effective and those unlikely to be effective; regimens 
unlikely to be effective were those for which there were 
no clinical trials data or international guidelines to support 
use in HIV-infected TB patients (e.g., a 3-drug regimen of 
isoniazid, rifampin, and ethambutol) or those that may be 
appropriate for drug-susceptible TB but were prescribed 
for patients infected with drug-resistant strains. This clas-
siﬁ  cation was done by investigators who were blinded to 
the patient’s treatment outcome.
Determination of Cause of Death
For patients who died during TB treatment, study staff 
obtained death certiﬁ  cates and medical records. Study staff 
also conducted a verbal autopsy for each patient. Verbal 
autopsies are a method for assessing causes of deaths, in-
cluding those related to TB and HIV, in resource-limited 
countries (27–32). They involve interviewing a family 
member or friend who was closely associated with the pa-
tient during the period preceding death. These respondents 
were asked when the patient ﬁ  rst became sick, what the 
symptoms were, how the patient died, and what the respon-
dent believed was the cause of death. At enrollment, pa-
tients entering the study consented to allow a family mem-
ber or friend to be interviewed in the event of their death. 
Likewise, the respondent also provided informed consent 
at the time of the interview. For patients who were lost to 
follow-up or transferred care to a facility not participating 
in the study, we reviewed the Thai government’s vital sta-
tus registry to determine whether they had died. Patients 
who died within 3 months and lost to follow-up or transfer 
were classiﬁ  ed as deaths during study follow-up.
A committee of 3 physicians not involved in care of 
the patients reviewed the records of all deceased patients, 
including study forms, verbal autopsy reports, death certiﬁ  -
cates, medical records, and laboratory data. These 3 physi-
cians reviewed cases together. A decision about the cause 
of death required agreement of 2 of the 3 physicians. After 
records review, the committee classiﬁ  ed the cause of death 
as 1 of the following: TB, an HIV-related condition (not 
TB), or a non-TB/HIV–associated condition. The commit-
tee also recorded what it believed to be the speciﬁ  c cause(s) 
of death and its level of certainty about this determination: 
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uncertain, possible, probable, or highly certain. The level 
of certainty was based on 3 primary criteria: 1) laborato-
ry, microbiologic, or pathologic evidence of the cause of 
death; 2) agreement between the physician panel and the 
cause of death as recorded on the death certiﬁ  cate or medi-
cal records; and 3) no other cause that was equally likely 
to have caused death. High certainty required all 3 of these 
criteria, probable required 2 of the 3, possible required 1, 
and uncertain was used for cases that lacked all 3 criteria. 
For some cases, the committee determined that the patient 
did not have TB. In these cases, there was no microbiologic 
evidence of TB, and the patient often had another condition 
that would explain the symptoms reported. Because TB 
programs would not have detected that patients undergoing 
treatment did not have TB, the patients therefore would still 
be registered. This retention is necessary because results 
should apply broadly to all HIV-infected persons registered 
for TB treatment.
Data Analysis
We described causes of death for all patients who died, 
stratiﬁ  ed by level of certainty (highly certain and probable 
vs. possible and uncertain). We then compared causes of 
death for patients who died <60 days after TB diagnosis 
with those who died >60 days after TB diagnosis. Patients 
with evidence of disease in multiple sites were classiﬁ  ed 
as having disseminated disease. TB localized to the central 
nervous system or abdomen was classiﬁ  ed as complicated.
For univariate analysis of categorical variables, we 
compared proportions using the χ2 test and, when appropri-
ate, the Fisher exact test. For multivariate analyses of the 
association between medications used and speciﬁ  c causes 
of death, we performed a Cox proportional hazards mul-
tivariate analysis, after ﬁ  rst conﬁ  rming that the assump-
tions of the proportional hazards model were met. For this 
analysis, we excluded patients who died within 14 days af-
ter treatment initiation because we presumed these deaths 
were not preventable through medical treatment.
We created 4 separate models, 1 each for death caused 
by TB, death caused by an HIV-associated condition, death 
equally likely to be caused by TB or an HIV-associated 
condition, and death caused by a non-TB and non-HIV-
associated condition. The outcome of interest was death 
due to the speciﬁ  c cause with any level of certainty (and 
excluding those who died of other causes), compared with 
patients who were alive. Outcomes other than death were 
censored after 1 year of follow-up. 
We included data on use of CPT, ART, ﬂ  uconazole, 
and an effective TB regimen, and we controlled for CD4. 
For CPT, ART, and ﬂ  uconazole. Patients who had taken the 
medication for at least 14 days before their treatment out-
come were categorized as being on the medication, whereas 
those not on the medication or on it for <14 days were cat-
egorized as not being on the medication. We also assessed 
for confounding according to hospitalization at enrollment, 
hepatitis C antibody reactivity, abnormal liver enzymes, 
and type of TB (pulmonary, extrapulmonary without com-
plications, or disseminated/complicated extrapulmonary). 
We chose to assess for confounding among these variables 
because they were associated with risk for death in HIV-
infected TB patients in Thailand (CDC, unpub. data). We 
developed our ﬁ  nal models by using forward, step-wise 
variable selection, keeping variables with p<0.05 and those 
that modiﬁ  ed the hazard ratios (HRs) by >10%.
Results
From May 1, 2005, through September 30, 2007, we 
enrolled 849 patients, of whom 142 (17%) died during TB 
treatment. Another 150 (18%) patients either were lost to 
follow-up or transferred their care to a facility not partici-
pating in the study. Among patients who died, the ascribed 
cause of death was TB for 38 (27%), an HIV-associated 
condition other than TB for 50 (35%), and a condition not 
related to TB or HIV for 22 (15%). TB or an HIV-associat-
ed condition was equally likely in 32 (23%) patients. Of the 
142 patients who died, 23 (16%) were judged not to have 
had TB at all. Among the 74 patients for whom certainty 
about the cause of death was probable or highly certain, 
29 (39%) died of TB, 33 (45%) died of an HIV-associated 
condition, and 12 (16%) died of a condition not related to 
TB or HIV (Table 1).
Of the 38 patients who died of TB, 20 (53%) had dis-
seminated TB, including 3 who had disseminated multi-
drug-resistant (MDR) TB. Including those 3, a total of 6 
(16%) had MDR TB. Seven patients had TB involving the 
central nervous system, including 2 with radiculomyelitis 
and 1 with MDR TB meningitis (Table 2).
Patients with HIV-associated deaths had a wide range 
of diagnoses. Among the 50 patients who died of an HIV-
related cause other than TB, 10 (20%) died of nontuber-
culous mycobacterial infections, 7 (14%) died of PCP, 
and 8 (16%) died of other fungal infections (including 5 
with cryptococcal meningitis) (Table 2). Of the 10 patients 
whose cause of death was determined to be nontuberculous 
mycobacteria (NTM), 4 had NTM isolated from a normally 
sterile site (2 from blood, 1 from bone marrow, 1 from a 
lymph node). NTM was isolated from sputum in 5 of the 
remaining patients and stool in the other.
A total of 32 patients died of a condition that was 
equally likely to be TB- or HIV-related, including 6 (19%) 
ascribed to disseminated mycobacterial disease. These di-
agnoses were based on multiple specimens being positive 
for acid-fast bacilli but no mycobacterial culture conﬁ  rma-
tion or identiﬁ  cation. Finally, 22 patients died of a non-TB, 
non-HIV–associated condition, including 11 (50%) who 
died of liver disease (Table 2).
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The distribution of causes of death varied when strati-
ﬁ  ed by time from TB treatment initiation. When limited 
to the 74 patients for whom the cause of death was known 
with high or probable certainty, 18 (55%) of 33 deaths oc-
curring <60 days after TB treatment initiation were caused 
by TB, compared with 11 (27%) of 41 deaths occurring 
>60 days after TB treatment initiation (p = 0.02). Of the 41 
persons who died >60 days after initiating TB treatment, 23 
(56%) died of an HIV-related condition, compared with 10 
(30%) of the 33 patients who died <60 days after TB treat-
ment initiation (p = 0.03). 
The median CD4 for all patients enrolled was 55 (inter-
quartile range [IQR] 18–142). Among patients who did not 
die, the median CD4 was 66 cells/μL (IQR 26–169). Medi-
an CD4 was 23 cells/μL (IQR 8.5–96) for persons who died 
of TB (p<0.01 for comparison with patients who did not 
die), 18 cells/μL (IQR 8–41) for those who died of an HIV-
associated condition other than TB (p <0.01), 18 cells/μL 
(IQR 4–40) for those in whom TB and an HIV-associated 
cause of death other than TB were equally likely (p<0.01), 
and 63 cells/μL (IQR 18–112) among persons who died of 
a non-TB, non-HIV-associated cause (p = 0.18).
Use of ART, opportunistic infection prophylaxis, and 
an effective TB regimen, along with other characteristics 
had varying associations with death due to different causes. 
Of the 849 patients enrolled in the study, 371 (44%) re-
ceived ART. Among the 142 patients who died, 36 (25%) 
received ART; 335/707 (47%) of persons not known to 
have died received ART. The risk for death caused by TB 
was lower for persons who took ART (HR 0.2, 95% con-
ﬁ  dence interval [CI], 0.1–0.5) and higher for patients who 
were prescribed an ineffective TB regimen (HR 5.0, 95% 
CI 2.0–12.6) and for those who were hospitalized at enroll-
ment (HR 11.9, 95% CI 4.4–32.1). For death due to HIV-
associated causes, ART was associated with decreased risk 
for death (HR 0.4, 95% CI 0.2–0.7), and being prescribed 
an ineffective TB regimen was associated with increased 
risk for death (HR 2.6, 95% CI 1.4–5.1). For patients in 
whom death due to TB or an HIV-associated cause was 
equally likely, the risk for death was lower for persons who 
were prescribed ART (HR 0.04, 95% CI 0.01–0.3) and 
ﬂ  uconazole (HR 0.4, 95% CI 0.2–0.98). Decreased CD4 
was associated with risk for death in all of these analyses, 
but use of CPT was not. ART, ﬂ  uconazole, CPT, ineffec-
tive TB treatment, and CD4 were not associated with risk 
for death from a non-TB, non–HIV-associated cause, but 
hepatitis C antibody reactivity and abnormal liver enzymes 
were associated with increased risk for death in this group 
(Table 3).
Discussion
Among HIV-infected persons with a TB diagnosis in 
Thailand, we found that TB-related deaths were most com-
mon within the ﬁ  rst 2 months after initiation of TB treat-
ment, but overall, >50% of all deaths occurring during TB 
treatment were not caused by TB, and some patients actu-
ally did not have TB. Multiple interventions are needed, 
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Table 1. Causes of death, stratified by level of certainty, for all enrolled patients who died, Thailand, 2005–2007* 
Level of certainty, no. (%) patients
Cause of death Probable or high, n = 74  Possible or uncertain, n = 68 
Total no. (%) patients, 
N = 142
TB 29 (39) 9 (13) 38 (27)
HIV-associated condition (not TB) 33 (45) 17 (25) 50 (35)
TB or HIV-associated equally likely 0 32 (47) 32 (23)
Not TB or HIV-associated 12 (16) 10 (15) 22 (15)
*TB, tuberculosis. 
Table 2. Causes of death for all enrolled patients who died (N = 
142), Thailand, 2005–2007* 
Cause of death  No. (%) patients 
TB 38 (27)
  Disseminated TB (3 with MDR TB)  20 (53) 
  Central nervous system TB  
  (1 with MDR TB) 
7 (18) 
  Pulmonary TB (2 with MDR TB)  10 (26) 
  Peritoneal TB  1 (3) 
HIV-associated condition  50 (35) 
  Bacterial infection  6 (12) 
  Cerebral toxoplasmosis  4 (8) 
  Disseminated CMV  1 (2) 
  Fungal infection (other than PCP)  8 (16) 
  Liver disease  1 (2) 
 Nontuberculous  mycobacteria  10  (20) 
 PCP  7  (14) 
  Other infectious cause  5 (10) 
  Other noninfectious cause  1 (2) 
 Unknown  7  (14) 
TB or HIV-associated condition equally likely  32 (23) 
 Disseminated  mycobacterial  disease
  (TB vs. NTM) 
6 (19) 
  Liver disease  1 (3) 
  Other infectious cause  3 (9) 
  Other noninfectious cause  1 (3) 
 Unknown  21  (66) 
Non-TB/HIV–associated condition  22 (15) 
  Bacterial infection  1 (5) 
  Liver disease  11 (50) 
  Stevens-Johnson syndrome  2 (9) 
  Other infectious cause  1 (5) 
  Other noninfectious cause  6 (27) 
 Unknown  1  (5) 
*TB, tuberculosis; MDR TB, multidrug-resistant TB; CMV, 
cytomegalovirus; PCP, Pneumocystis jirovecii pneumonia; NTM, 
nontuberculous mycobacteria. RESEARCH
therefore, to reduce death rates in HIV-infected TB patients 
in Thailand.
Among patients who died of TB, delayed TB diagno-
sis may be partially responsible.. Of the 38 patients who 
died of TB, 30 had disseminated TB, MDR-TB, or com-
plicated extrapulmonary TB, conditions that are difﬁ  cult 
to diagnose, occur frequently in HIV-infected persons, and 
have high death rates (13,33,34). Hospitalization at enroll-
ment was strongly associated with increased risk for death 
caused by TB but not death due to other causes, which fur-
ther suggests that delay in TB diagnosis may be partially 
responsible. The World Health Organization recommends 
that countries with TB/HIV syndemics intensify TB case 
ﬁ  nding in HIV-infected persons and expand access to TB 
culture and drug-susceptibility testing (1,35). If implement-
ed broadly, these strategies could reduce TB-related deaths 
by diagnosing TB before it is disseminated and severe and 
by allowing early initiation of second-line TB treatment for 
drug-resistant TB. Expansion in laboratory capacity and 
case ﬁ  nding will also need to be coupled to physician train-
ing. We found that use of regimens that are not standard 
or not tailored to the drug-susceptibility pattern of the TB 
strain was an important risk factor for death. 
We also found that using ART during TB treatment 
was associated with reduced death rates both from TB 
and from non-TB, HIV-associated conditions. Previous 
epidemiologic studies in Thailand and other countries have 
demonstrated marked improvement in duration of survival 
among HIV-infected TB patients treated with ART during 
TB treatment (2,7,16,36–38). Our study conﬁ  rms this ﬁ  nd-
ing and suggests that ART use most likely would dramati-
cally reduce both early and late deaths. Clinical trials are 
currently attempting to identify the optimum time to initi-
ate ART during TB treatment (39).
Among HIV-related causes of death other than TB, the 
most common causes were NTM disease and fungal infec-
tions. For the 4 patients who had NTM isolated from nor-
mally sterile sites, NTM most likely was a causative factor, 
but the role is less clear in those in whom it was isolated from 
sputum or stool. Expanding mycobacterial culture capacity 
will help better assess the impact of NTM disease in Asia 
because NTM may be an underappreciated cause of death 
among patients clinically diagnosed with TB (40). Fungal 
infections may be preventable with prophylactic antifun-
gal treatment; a previous analysis of risk factors for death 
in Thailand found that ﬂ  uconazole was associated with im-
proved duration of survival (16). Controlled trials of antifun-
gal prophylaxis may be needed to assess whether it increases 
survival rates among HIV-infected TB patients in Asia.
Although ART is associated with improved survival 
and ﬂ  uconazole may be associated with reduced risk of 
some causes of death, CPT was not associated with reduced 
risk for death from any cause. This ﬁ  nding is consistent 
with that of several other observational studies from South-
east Asia in the era of ART (2,16; CDC, unpub. data). It 
is possible that the differing epidemiology of opportunistic 
infections in the region makes CPT less beneﬁ  cial or not 
beneﬁ  cial at all, or that these studies, none of which were 
randomized controlled trials, were not adequately con-
trolled or powered to detect a meaningful difference. Ran-
domized controlled trials of the efﬁ  cacy of CPT in patients 
receiving ART may be needed in Southeast Asia.
In addition to these speciﬁ  c interventions, which could 
address the speciﬁ  c causes of death identiﬁ  ed in this study, 
other interventions could decrease the high, early death 
rates observed in persons with HIV and a diagnoses of 
TB. First, the median CD4 count among all patients in this 
study was low. Earlier diagnosis of HIV through regular 
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Table 3. Adjusted hazard ratios for associations between patient characteristics and causes of death among enrolled patients, 
Thailand, 2005–2007*  
Patient characteristic 
Death caused by TB, 
n = 723† 
Death caused by  
non-TB HIV-associated 
cause, n = 745† 
Death caused by TB  
or HIV equally likely,  
n = 726† 
Death caused by  
non-TB/HIV condition, 
n = 719† 
Used ART‡  0.2 (0.1–0.5)§  0.4 (0.2–0.7)§  0.04 (0.01–0.3)§  0.9 (0.3–2.6) 
Used CPT‡  0.5 (0.1–1.5)  1.0 (0.3–3.2)  1.0 (0.3–3.5)  1.1 (0.2–5.5) 
Used fluconazole‡  0.5 (0.2–1.2)  0.8 (0.4–1.6)  0.4 (0.2–0.98)§  1.2 (0.4–3.8) 
CD4 0.993 (0.987–0.999)§  0.987 (0.980–0.994)§  0.988 (0.981–0.996)§  1.0 (0.996–1.004) 
Ineffective TB regimen¶  5.0 (2.0–12.6)§  2.6 (1.4–5.1)§  0.3 (0.04–2.3)  0.9 (0.2–3.7) 
Hepatitis C antibody positive  Not included  Not included  Not included  3.2 (1.2–8.3)§ 
Hospitalized at enrollment  11.9 (4.4–32.1)§  Not included  Not included  Not included 
Abnormal liver enzyme levels#  Not included  Not included  Not included  5.3 (2.2–12.9)§ 
*TB, tuberculosis; ART, antiretroviral therapy; CPT, cotrimoxazole preventive therapy; CD4, CD4+ T-cell lymphocyte count; Not included, not retained in 
final model. Patient counts exclude 27 persons who died within 14 days of TB treatment initiation and 13 patients with missing CD4. 
†Each model includes all patients who survived plus those who died of the specific cause noted (in each category, patients who died of any of the other 3 
causes were excluded). Values in parentheses are 95% confidence intervals. 
‡Must have been taken for >14 days to qualify as taking medication. 
§p<0.05. 
¶Ineffective regimens were those without supportive clinical trials data, without international guidelines, or not likely to work because of the drug-
resistance pattern of the patient’s isolate. 
#Aspartate transaminase >120 units/L and/or alanine aminotransferase >165 units/L and/or bilirubin >2 mg/dL.  HIV-infected Persons with TB, Thailand
provider-initiated testing and counseling of TB patients and 
earlier HIV testing of other persons combined with earlier 
initiation of ART would result in less immunocompromise 
and less risk for many of the opportunistic infections found 
in this population. Next, the impact of TB/HIV can be re-
duced by prevention of TB in persons with HIV (e.g., im-
proved infection control measures in HIV care settings and 
use of isoniazid preventive therapy) and prevention of HIV 
in TB patients through appropriate counseling messages 
targeting persons with HIV and without HIV. 
No method of assessing causes of death is completely 
reliable, particularly in resource-limited countries where 
microbiologic testing and postmortem examinations are 
infrequently performed and many patients die outside of 
hospitals. We used several imperfect data sources in com-
bination—verbal autopsy, medical record review, death 
certiﬁ  cate data—to identify the cause of death. Both missed 
diagnoses and false diagnoses may have skewed our ﬁ  nd-
ings, but we could not determine the magnitude and im-
pact of these problems without independent veriﬁ  cation of 
the cause of death. Physicians determining cause of death 
could have been inﬂ  uenced by their own biases, but our use 
of a panel of physicians and criteria for ascribing causes 
should have limited this possibility. Finally, some provid-
ers did not always use available microbiologic tests, includ-
ing blood culture. Failure to use these tests may result in 
underestimation of some causes of death.
We found that TB-related and HIV-related deaths are 
likely to be reduced through early initiation of ART and 
of appropriate anti-TB drug regimens. Expanded use of 
modern TB diagnostics may also improve survival by di-
agnosing TB before it is disseminated and severe, identify-
ing drug resistance early, and differentiating between TB, 
NTM, and other causes of illness. Finally, improvements 
in general HIV care and treatment, including earlier HIV 
testing and ART use along with appropriate measures to 
prevent TB and HIV, should decrease the high early death 
rates observed.
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